Axatilimab is pending FDA approval for cGVHD after failure of at least 2 prior lines of systemic therapy. Discuss its mechanism of action (MOA) and how this MOA might add value to cGVHD treatment landscape.
Discuss phase 1/2 data (Kitko CL, et al. J Clin Oncol. 2022) and AGAVE-201 trial data with axatilimab for cGVHD (Wolff D, et al. ASH 2023).